Spinal technology company VB Spine has received two 510(k) clearances from the FDA to expand the indications for its Vitoss Bone Graft Substitute and interbody cage portfolio.
The new clearances allow the Vitoss substitute to be used in the intervertebral disc space with interbody cages, and expands the indications for the company’s interbody cages to include use with bone void fillers cleared for use in intervertebral body fusion procedures, according to a July 29 news release from VB Spine.
Vitoss, which has previously been used as a bone graft in the extremities, pelvis and posterolateral spine, can now also be used in the anterior column of the spine including interbody cages.
The expanded indication provides surgeons with an alternative to autografts, avoiding the need for a second surgical site, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.